Effectiveness of Human Atrial Natriuretic Peptide Supplementation in Pulmonary Edema Patients Using the Pulse Contour Cardiac Output System

다국어 초록 (Multilingual Abstract)

Purpose: Atrial natriuretic peptide (ANP) has a variety of pharmacologic effects,including natriuresis, diuresis, vasodilatation, and suppression of the reninangiotensin system. A recent study showed that ANP infusion improved hypoxemia and pulmonary hypertension in a lung injury model. On the other hand, the pulse contour cardiac output (PiCCOTM) system (Pulsion Medical Systems, Munich, Germany) allows monitoring of the intravascular volume status and may be used to guide volume therapy in severe sepsis and critically ill patients. Materials and Methods: We treated 10 pulmonary edema patients without heart disease with human ANP (HANP). The patients were divided into two groups: a group with normal Intrathoracic Blood Volume (ITBV) (900-1100mL/m2) (n = 6), and a group with abnormal ITBV (n = 4), as measured by the PiCCOTM device; the extravascular lung water (EVLW) and pulmonary vascular permeability index (PVPI) in the two groups were compared. Results: The average patient age was 63.9 ± 14.4 years. The normal ITBV group showed significant improvement of the EVLW (before, 16.7 ± 2.7 mL/kg; after, 10.5 ± 3.6mL/kg; p = 0.0020) and PVPI (before, 3.2 ± 0.3; after, 2.1 ± 0.7; p = 0.0214) after the treatment. The abnormal ITBV group showed no significant improvement of either the EVLW (before, 16.3 ± 8.9 mL/kg; after, 18.8 ± 9.6 mL/kg; p = 0.8387)or PVPI (before, 2.3 ± 0.8; after, 2.7 ± 1.3; p = 0.2782) after the treatment. In both groups, the EVLW and PVPI were strongly correlated with the chest X-ray findings. Conclusion: We conclude that HANP supplementation may improve the EVLW and PVPI in pulmonary edema patients without heart disease with a normal ITBV. The PiCCOTM system seems to be a useful device for the management of pulmonary edema.

참고문헌 (Reference)

1 Tanabe M, "The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model" 154 : 1351-1356, 1996

2 Langman CB, "The diuretic phase of respiratory distress syndrome and its relationship to oxygenation" 98 : 462-466, 1981

3 Imamura T, "Prorective effect of aipha-human atrial natriuretic polypeptide (alpha-hANP) on chemical induced pulmonary edema" 42 : 403-414, 1988

4 Sumi K, "Human atrial natriuretic peptide prevents the increase in pulmonary artery pressure associated with aortic unclamping during abdominal aortic aneurysmectomy" 22 : 204-209, 2008

5 Tanabe M, "Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide" 22 : 1762-1768, 1994

6 Heaf DP, "Changes in pulmonary function during the diuretic phase of respiratory distress syndrome" 101 : 103-107, 1982

7 Mitaka C, "Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury" 114 : 223-228, 1998

8 Michard F, "Bedside assessment of extravascular lung water by dilution methods: temptations and pitfalls" 35 : 1186-1192, 2007

9 Needleman P, "Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis" 314 : 828-834, 1986

10 Baron DA, "Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers" 86 : 3394-3398, 1989

11 Lofton CE, "Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability" 23 : 919-927, 1991

12 Berkowitz DM, "Accurate characterization of extravascular lung water in acute respiratory distress syndrome" 36 : 1803-1809, 2008